Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1329-1336

  Kuruvilla, John ^a,b   Pintilie, Melania ^a   Tsang, Richard ^a   Nagy, Tracy ^b   Keating, Armand ^a,b   Crump, Michael ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Autologous Blood and Marrow Transplant Programme   (Canada)

Author keywords

Primary mediastinal large B cell lymphoma; Salvage chemotherapy; Stem cell transplant

Indexed keywords

ANTHRACYCLINE; ARABINOSIDE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PLATINUM COMPLEX; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CHEMOSENSITIVITY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 47649096219     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802108870     Document Type: Article

References (41)

1. Banks, P. M. and Warnke, R. A. (2001) Mediastinal (thymic) large B-cell lymphoma. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues, pp. 175-178. IARC Press, Lyon
2. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. Cleary, M. L. et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, pp. 1361-1392.
3. Isaacson, P. G., Norton, A. J. and Addis, B. J. (1987) The human thymus contains a novel population of B lymphocytes. Lancet, 2, pp. 1488-1491.
4. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P. Gascoyne, R. D. et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med, 198, pp. 851-862.
5. Savage, K. J., Monti, S., Kutok, J. L., Cattoretti, G., Neuberg, D. De Leval, L. et al. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, pp. 3871-3879.
6. Haioun, C., Gaulard, P., Roudot-Thoraval, F., Divine, M., Jouault, H. Lebourgeois, J. P. et al. (1989) Mediastinal diffuse large-cell lymphoma with sclerosis: A condition with a poor prognosis. Am J Clin Oncol, 12, pp. 425-429.
7. Lavabre-Bertrand, T., Donadio, D., Fegueux, N., Jessueld, D., Taib, J. Charlier, D. et al. (1992) A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer, 69, pp. 2561-2566.
8. Lazzarino, M., Orlandi, E., Paulli, M., Boveri, E., Morra, E. Brusamolino, E. et al. (1993) Primary mediastinal B-cell lymphoma with sclerosis: An aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol, 11, pp. 2306-2313.
9. Lazzarino, M., Orlandi, E., Paulli, M., Strater, J., Klersy, C. Gianelli, U. et al. (1997) Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: A multicenter study of 106 patients. J Clin Oncol, 15, pp. 1646-1653.
10. Todeschini, G., Ambrosetti, A., Meneghini, V., Pizzolo, G., Menestrina, F. Chilosi, M. et al. (1990) Mediastinal large-B-cell lymphoma with sclerosis: A clinical study of 21 patients. J Clin Oncol, 8, pp. 804-808.
11. Cazals-Hatem, D., Lepage, E., Brice, P., Ferrant, A., d'Agay, M. F. Baumelou, E. et al. (1996) Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol, 20, pp. 877-888.
12. Zinzani, P. L., Martelli, M., Magagnoli, M., Pescarmona, E., Scaramucci, L. Palombi, F. et al. (1999) Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) Gallium scan in 50 patients. Blood, 94, pp. 3289-3293.
13. Todeschini, G., Secchi, S., Morra, E., Vitolo, U., Orlandi, E. Pasini, F. et al. (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer, 90, pp. 372-376.
14. Zinzani, P. L., Martelli, M., Bertini, M., Gianni, A. M., Devizzi, L. Federico, M. et al. (2002) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica, 87, pp. 1258-1264.
15. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M. Imrie, K. et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7, pp. 379-391.
16. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. Bron, D. et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
17. Cairoli, R., Grillo, G., Tedeschi, A., Gargantini, L., Marenco, P. Tresoldi, E. et al. (2002) Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant, 29, pp. 473-477.
18. Sehn, L. H., Antin, J. H., Shulman, L. N., Mauch, P., Elias, A. Kadin, M. E. et al. (1998) Primary diffuse large B-cell lymphoma of the mediastinum: Outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood, 91, pp. 717-723.
19. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. Mize, E. M. et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
20. Velasquez, W. S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M. Tucker, S. et al. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, pp. 117-122.
21. Rodriguez-Monge, E. J. and Cabanillas, F. (1997) Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am, 11, pp. 937-947.
22. Crump, M., Baetz, T., Couban, S., Belch, A., Marcellus, D. Howson-Jan, K. et al. (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer, 101, pp. 1835-1842.
23. Girouard, C., Dufresne, J., Imrie, K., Stewart, A. K., Brandwein, J. Prince, H. M. et al. (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol, 8, pp. 675-680.
24. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. Connors, J. M. et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
25. Mollee, P., Pereira, D., Nagy, T., Song, K., Saragosa, R., Keating, A. and Crump, M. (2002) Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant, 30, pp. 273-278.
26. Weaver, C. H., Hazelton, B., Birch, R., Palmer, P., Allen, C. Schwartzberg, L. et al. (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood, 86, pp. 3961-3969.
27. Gopal, A. K., Gooley, T. A., Golden, J. B., Maloney, D. G., Bensinger, WI Petersdorf S, H et al. (2001) Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant, 27, pp. 593-599.
28. Watts, M. J., Sullivan, A. M., Leverett, D., Peniket, A. J., Perry, A. R. Williams, C. D. et al. (1998) Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol, 16, pp. 1554-1560.
29. Schwella, N., Beyer, J., Schwaner, I., Heuft, H. G., Rick, O. Huhn, D. et al. (1996) Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol, 14, pp. 1114-1121.
30. Kiss, J. E., Rybka, W. B., Winkelstein, A., deMagalhaes-Silverman, M., Lister, J. D'Andrea, P. et al. (1997) Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant, 19, pp. 303-310.
31. Haas, R., Mohle, R., Fruhauf, S., Goldschmidt, H., Witt, B. Flentje, M. et al. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood, 83, pp. 3787-3794.
32. Vose, J. M., Zhang, M. J., Rowlings, P. A., Lazarus, H. M., Bolwell, B. J. Freytes, C. O. et al. (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol, 19, pp. 406-413.
33. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
34. Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D. Noy, A. et al. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, pp. 3684-3688.
35. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J. Bormans, G. et al. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, pp. 53-59.
36. Guiter, C., Dusanter-Fourt, I., Copie-Bergman, C., Boulland, M. L., Le Gouvello, S Gaulard, P. et al. (2004) Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood, 104, pp. 543-549.
37. Feuerhake, F., Kutok, J. L., Monti, S., Chen, W., LaCasce, A. S. Cattoretti, G. et al. (2005) NF-κB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood, 106, pp. 1392-1399.
38. Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C Sausville, E. et al. (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res, 7, pp. 1419-1428.
39. Lam, L. T., Davis, R. E., Pierce, J., Hepperle, M., Xu, Y. Hottelet, M. et al. (2005) Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res, 11, pp. 28-40.
40. Savage, K. J., Al-Rajhi, N., Voss, N., Paltiel, C., Klasa, R. Gascoyne, R. D. et al. (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol, 17, pp. 123-130.
41. Vellenga, E., van Putten, W. L., van't Veer, M B, Zijlstra, J. M., Fibbe, W. E. van Oers, M. H. et al. (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood, 111, pp. 537-543.